Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...
An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback